Product image of Montelukast Ratiopharm (Montelukast) supplied by GNH India

Montelukast Ratiopharm

Active Ingredient:
Montelukast
Origin:
EU

Montelukast Ratiopharm (Montelukast)

Montelukast, the active ingredient in Montelukast Ratiopharm, is a leukotriene receptor antagonist presented as a tablet for oral use. It is indicated for the management of asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children who require controller therapy.

GNH India supplies Montelukast Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva Pharma S.L.U.,

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms.

  • Asthma: improves control of chronic airway obstruction and reduces exacerbations.
  • Allergic rhinitis: relieves nasal congestion, sneezing and itching caused by seasonal or perennial allergens.
  • Exercise‑induced bronchoconstriction: prevents narrowing of the airways that occurs during or after physical activity.

How It Works

  • Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1, blocking the binding of leukotriene D4 and related mediators. By inhibiting this receptor, it reduces bronchoconstriction, vascular permeability, mucus secretion and eosinophilic inflammation that contribute to asthma and allergic rhinitis symptoms.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate pain often reported during treatment.
  • Abdominal pain: discomfort or cramping in the stomach region.
  • Nausea: feeling of queasiness that may lead to vomiting.
  • Diarrhoea: loose, watery stools occurring intermittently.
  • Cough: persistent dry cough without infection.
  • Sore throat: irritation or pain in the throat.

Serious or Rare Side Effects

  • Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention.
  • Neuropsychiatric events: mood changes, depression, anxiety or suicidal thoughts.
  • Hepatic enzyme elevation: abnormal liver function tests indicating possible liver stress.
  • Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Assess liver function: evaluate hepatic status, especially in patients with known liver disease.
  • Monitor neuropsychiatric symptoms: watch for mood alterations, depression or suicidal ideation.
  • Use caution in severe hepatic impairment: dosage adjustment may be required.
  • Avoid in patients with known hypersensitivity to montelukast or any component of the formulation.
  • Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Montelukast may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Ritonavir: can increase montelukast plasma concentrations, raising risk of side effects.
  • Phenobarbital: may markedly reduce montelukast exposure, diminishing therapeutic effect.
  • Carbamazepine: strong enzyme inducer that can lower montelukast levels.

Moderate Interactions (Monitor Closely)

  • Warfarin: potential alteration of INR; monitor coagulation parameters.
  • Theophylline: possible change in plasma levels; adjust dose if needed.
  • Inhaled corticosteroids: may increase risk of neuropsychiatric events; observe patient closely.

Frequently Asked Questions

Montelukast Ratiopharm is prescribed to manage asthma, relieve symptoms of allergic rhinitis and prevent exercise‑induced bronchoconstriction. It works as a controller medication that reduces airway inflammation and allergic responses, helping patients achieve better respiratory control.

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 and related compounds from binding. This inhibition reduces bronchoconstriction, mucus production, vascular leakage and eosinophil recruitment, which together lessen asthma attacks and allergic nasal symptoms.

The specific dose of Montelukast Ratiopharm is determined by the prescribing healthcare professional based on the patient’s age, weight, condition severity and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast in pregnancy and lactation are limited. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss their individual situation with a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or those who prefer a once‑daily tablet, though it may be less potent for acute symptom relief compared with inhaled steroids.

Montelukast Ratiopharm tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and avoid storing in bathrooms or other humid environments.

The medication is taken orally, usually as a whole tablet with or without food, once daily at the same time each day. Patients should swallow the tablet whole and not crush or chew it unless otherwise directed by a healthcare professional.

Serious risks include rare allergic reactions such as angioedema or anaphylaxis, and neuropsychiatric events like depression, anxiety, or suicidal thoughts. Any sudden mood changes, rash, or breathing difficulties should prompt immediate medical evaluation.

Montelukast Ratiopharm is contraindicated in individuals with a known hypersensitivity to montelukast or any excipients in the tablet. Patients with severe hepatic impairment should use it only under close medical supervision, and it should be avoided in those who have experienced serious allergic reactions to the drug.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT